Recently, in patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) with a poor yield of CD34+ cells, the new drug plerixafor (Mozobil®) can be administered before apheresis to increase the number of circulating CD34+ cells. Here, CD34 is linked to non-Hodgkin lymphoma.